Intellia Therapeutics is to broaden its reach in oncology immunotherapy by combining its expertise in CRISPR gene-editing with allogeneic natural killer (NK) cell therapies being developed by ONK Therapeutics.
Intellia’s most eye-catching venture is groundbreaking in vivo gene-editing program NTLA-2001, which it could file later this year, but it...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
